Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$105.77
+0.5%
$97.90
$36.65
$130.05
$8.68B1.95742,490 shs91,083 shs
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$41.54
+1.5%
$39.16
$13.62
$44.28
$1.99B0.94350,830 shs54,373 shs
Sanofi stock logo
SNY
Sanofi
$41.72
-7.0%
$43.50
$40.89
$52.68
$101.23B0.343.60 million shs4.71 million shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$32.40
-0.3%
$36.97
$19.07
$56.05
$2.33B0.921.38 million shs327,132 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-0.86%-4.61%-3.72%+29.83%+140.85%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-2.43%-0.94%+1.36%+23.57%+165.50%
Sanofi stock logo
SNY
Sanofi
-1.52%+2.42%+3.27%-3.71%-9.12%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-2.43%-9.84%-24.66%-8.71%+56.90%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$105.77
+0.5%
$97.90
$36.65
$130.05
$8.68B1.95742,490 shs91,083 shs
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$41.54
+1.5%
$39.16
$13.62
$44.28
$1.99B0.94350,830 shs54,373 shs
Sanofi stock logo
SNY
Sanofi
$41.72
-7.0%
$43.50
$40.89
$52.68
$101.23B0.343.60 million shs4.71 million shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$32.40
-0.3%
$36.97
$19.07
$56.05
$2.33B0.921.38 million shs327,132 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-0.86%-4.61%-3.72%+29.83%+140.85%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-2.43%-0.94%+1.36%+23.57%+165.50%
Sanofi stock logo
SNY
Sanofi
-1.52%+2.42%+3.27%-3.71%-9.12%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-2.43%-9.84%-24.66%-8.71%+56.90%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2.83
Moderate Buy$124.4818.27% Upside
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
2.92
Moderate Buy$57.8641.32% Upside
Sanofi stock logo
SNY
Sanofi
2.47
Hold$49.5010.37% Upside
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
2.77
Moderate Buy$84.58160.18% Upside

Current Analyst Ratings Breakdown

Latest KYMR, RAPP, SNY, and VERA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/30/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Initiated CoverageHold$120.00
7/28/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Boost Price TargetBuy$125.00 ➝ $135.00
7/28/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Initiated CoverageOutperform
7/17/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Reiterated RatingSell (D-)
7/17/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Reiterated RatingSell (D-)
7/17/2026
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Reiterated RatingSell (D-)
7/16/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Boost Price TargetOutperform$120.00 ➝ $140.00
7/16/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Reiterated RatingBuy$65.00
7/13/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
DowngradeOutperformSector Perform$106.00 ➝ $115.00
7/8/2026
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Boost Price TargetBuy$73.00 ➝ $78.00
7/8/2026
Sanofi stock logo
SNY
Sanofi
Set Price Target$49.00
(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$39.21M220.81N/AN/A$19.42 per share5.42
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/A$10.17 per shareN/A
Sanofi stock logo
SNY
Sanofi
$49.35B2.20$6.95 per share6.45$33.26 per share1.35
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/A$8.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$111.48M-$2.60N/AN/AN/AN/A-24.78%-23.44%8/6/2026 (Estimated)
Sanofi stock logo
SNY
Sanofi
$8.84B$3.5812.538.641.1516.95%13.39%7.58%7/30/2026 (Estimated)
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$299.61M-$5.54N/AN/AN/AN/A-74.86%-60.18%8/4/2026 (Estimated)

Latest KYMR, RAPP, SNY, and VERA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.7171N/AN/AN/A$32.17 millionN/A
8/6/2026Q2 2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$0.93N/AN/AN/A$20.00 millionN/A
8/4/2026Q2 2026
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$1.60N/AN/AN/A$1.28 millionN/A
7/30/2026Q2 2026
Sanofi stock logo
SNY
Sanofi
$1.10$1.1930+$0.0930$0.17$12.44 billion$14.04 billion
5/7/2026Q1 2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$0.56-$0.42+$0.14-$0.42$7.50 million$20.00 million
5/7/2026Q1 2026
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$1.3284-$1.69-$0.3616-$1.69$0.43 millionN/A
4/30/2026Q1 2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/AN/A
Sanofi stock logo
SNY
Sanofi
$1.763.92%+6.46%49.16%N/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
10.81
10.81
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A
27.08
27.08
Sanofi stock logo
SNY
Sanofi
0.17
1.01
0.22
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
0.15
13.64
13.64

Institutional Ownership

CompanyInstitutional Ownership
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A
Sanofi stock logo
SNY
Sanofi
14.03%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
99.21%

Insider Ownership

CompanyInsider Ownership
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
15.98%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
12.48%
Sanofi stock logo
SNY
Sanofi
1.00%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
15.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17082.26 million69.11 millionOptionable
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A47.83 million41.86 millionN/A
Sanofi stock logo
SNY
Sanofi
74,8462.42 billion2.40 billionOptionable
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
4071.78 million60.37 millionOptionable

Recent News About These Companies

Vera Therapeutics Inc - Ordinary Shares - Class A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$105.77 +0.52 (+0.49%)
As of 11:29 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Rapport Therapeutics stock logo

Rapport Therapeutics NASDAQ:RAPP

$41.54 +0.60 (+1.47%)
As of 11:29 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Sanofi stock logo

Sanofi NASDAQ:SNY

$41.72 -3.13 (-6.98%)
As of 11:29 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Vera Therapeutics stock logo

Vera Therapeutics NASDAQ:VERA

$32.40 -0.11 (-0.33%)
As of 11:29 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.